Novartis reported that its antibody drug Cosentyx did not meet the primary endpoint in a Phase 3 trial for giant cell arteritis, failing to beat placebo. The drug was in development as an alternative to existing treatments from Roche and AbbVie for this autoimmune disorder involving blood vessel inflammation. The negative result is a setback for Novartis’ efforts to expand Cosentyx’s indications into rare vascular conditions.